Log in Start free →
Today’s CSR movers
FOX 3.9 ▲ 1.5
C 4.0 ▲ 1.2
PCG 4.1 ▲ 1.2
IQV 4.6 ▲ 0.4
SWK 3.6 ▲ 0.4
ESS 3.7 ▲ 0.4
ES 2.2 ▼ 0.8
NWSA 4.0 ▼ 1.0
WEC 2.6 ▼ 1.2
ETR 2.9 ▼ 1.2
—
—
Health Care · NASDAQ NASDAQ · GILD

Gilead Sciences

$130.21 -$1.07 -0.82% CLOSE 07.31.26 AFTER HOURS $130.02
Convergence score
4.1 / 5.0 STRONG BULLISH
+0.0 vs last report
Overall valuation
Undervalued
Aggregated across multiple horizons
Consensus target (12mo)
$157.41 +20.9%
Range $120.00 — $180.00
Sector
Health Care
NASDAQ · Tracked daily
Today's snapshot

Where the signals stand.

REPORT 07.31.26
UV Convergence Score
REPORT 07.31.26
4.1
/ 5.0
STRONG BULLISH
Consensus signal A
4.0
Consensus signal B
4.0
Consensus signal D
4.0
Rating trend signal
4.5
Analyst average
4.3
Multi-signal aggregate How CSR works →
Day Range
$128.88 – $130.88
52W Range
$108.46 – $157.29
Volume
6.1M
Avg Vol
7.6M
Mkt Cap
$161.66B
P/E
17.72
EPS (TTM)
$7.35
Div Yield
2.50%
Beta
0.34
Today's convergence

Convergence score sits at 4.1 with overall valuation reading as undervalued. Drivers across the horizons inform the aggregate. Open the deep dives for valuation, analyst, or financial detail.

Valuation
Undervalued
CSR direction
STRONG BULLISH
Last close
$130.21
Sector
Health Care
Valuation
Three horizons
UPDATED 07.31.26
Short term
0–3 MO
No target Strong Buy
Medium term
3–12 MO
$158+21.3% Buy
Long term
12–36 MO
$175.85+35.1% Undervalued
Open valuation →
Analysts
Coverage & consensus
4 PANELS
Mean target (12mo)
$157.41 +20.9%
RANGE $120.00 — $180.00
Analyst consensus
Consensus rating Buy
Blended score 4.2 / 5
Analysts tracked 115
Open analysts →
Financials
Key metrics
LATEST
P/E
17.72
EPS (TTM)
$7.35
Mkt Cap
$161.66B
Div Yield
2.50%
Beta
0.34
52W Range
$108.46 – $157.29
Open financials →
Reports
Login for history

Sign in to view the historical report archive for this stock.

Log in →
Valuation breakdown

Three horizons, one consensus.

UPDATED 07.31.26
Short term
0–3 MO
Strong Buy
Consensus target
No target available

Current analyst consensus rating from Barchart.

Medium term
3–12 MO
Buy
Consensus target
$158 +21.3%
RANGE $120 – $180
$120NOW $130.21$180

12-month analyst consensus target across covering brokerages.

Long term
12–36 MO
Undervalued
Consensus target
$175.85 +35.1%

UVStocks in-house sector-relative valuation model.

Signal breakdown

What’s driving the score.

EACH SIGNAL RATED 1.0 — 5.0
Top-level breakdown
Valuation: PE Ratio: 17.72PEG Ratio: -DE Ratio: -
Free Cash Flow: $7.93BPB Ratio: -PS Ratio: -Dividend: $0.82
Analyst coverage

Blended analyst consensus & targets.

4 PANELS · UPDATED 07.31.26
Analyst consensus RATING · SCORE · PANELS · ANALYSTS
Rating Blended score Panels Analysts
Buy 4.2 4 115
Price targets LOW · MEAN · MEDIAN · HIGH · UPSIDE
Coverage Low Mean Median High Upside
All panels $120.00 $157.41 $160.00 $180.00 +20.9%
Rating distribution STRONG BUY · BUY · HOLD · SELL · STRONG SELL
Coverage SB B H S SS
All panels 6 41 11 0 0
Rating trend CURRENT VS 1M / 2M / 3M
Period Rating Avg Analysts
Current Strong Buy 4.47 30
1 Mo Ago Strong Buy 4.53 30
2 Mo Ago Strong Buy 4.56 32
3 Mo Ago Strong Buy 4.50 32
Most recent analyst action LATEST DESK ACTION
Date
7/29/2026
Firm
Cantor Fitzgerald
Action
Reiterated Rating
Rating
Overweight
Target
—
Related links
Financials

Full financial snapshot.

UPDATED 07.31.26
Quote snapshot 15 FIELDS
Prev Close
$131.28
Open
$130.76
Day Low
$128.88
Day High
$130.88
Bid
$123.02
Ask
$135.48
52W Low
$108.46
52W High
$157.29
50D Avg
$129.74
200D Avg
$131.71
Volume
6.1M
Avg Vol
7.6M
10D Avg Vol
6.2M
52W Change
15.99%
S&P 52W Change
19.23%
Valuation ratios 10 FIELDS
P/E (TTM)
17.72
P/E (Fwd)
13.54
PEG (Fwd)
2.14
P/S
5.44
P/B
6.88
Book Value
$18.93
EV/Revenue
5.85
EV/EBITDA
11.80
Mkt Cap
161.66B
Enterprise Val
173.94B
Profitability & returns 6 FIELDS
Profit Margin
30.99%
Gross Margin
79.37%
Operating Margin
39.28%
EBITDA Margin
49.56%
Return on Assets
13.29%
Return on Equity
43.36%
Growth 3 FIELDS
Revenue Growth (YoY)
4.40%
Earnings Growth (YoY)
54.80%
Earnings Growth (Q)
53.70%
Balance sheet & cash flow 11 FIELDS
Total Revenue
29.74B
EBITDA
14.74B
Total Cash
9.82B
Total Debt
22.17B
Cash / Share
$7.91
Revenue / Share
$23.92
Free Cash Flow
7.93B
Operating CF
10.81B
Debt / Equity
94.64
Current Ratio
1.97
Quick Ratio
1.54
Dividend 5 FIELDS
Fwd Dividend
3.28 (2.50%)
Dividend Yield
2.50%
Payout Ratio
43.40%
5Y Avg Yield
3.62%
Ex-Div Date
2026-06-15
Share statistics 7 FIELDS
Shares Out
1.24B
Float
1.24B
Shares Short
25.26M
% Short of Float
2.04%
Short Ratio
3.06
% Held Insiders
0.12%
% Held Institutions
92.12%
Calendar & events 5 FIELDS
Next Earnings
2026-08-04
Fiscal Year End
2025-12-31
Most Recent Qtr
2026-03-31
Last Split
2:1
Split Date
2013-01-28
Company 2 FIELDS
Industry
Drug Manufacturers - General
Employees
17,000